- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Reloxin marketing narrows
Scottsdale, Ariz. - Ipsen and Medicis have announced they will not pursue an agreement to commercialize Ipsen's Reloxin (botulinum toxin type A) outside the United States, Canada and Japan.
Scottsdale, Ariz. - Ipsen and Medicis have announced they will not pursue an agreement to commercialize Ipsen's Reloxin (botulinum toxin type A) outside the United States, Canada and Japan.
Medicis was unable to structure a European distribution network on mutually acceptable economic terms because of official pricing and reimbursement policies in Europe, the company said.
Reloxin, known as Dysport in Europe, is in phase 3 trials in the United States for treatment of glabellar lines. Medicis aims to file for Food and Drug Administration approval in 2007.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
